Table 2

Summary table with results (monotherapy)

	Entry criteria HbA1c (%)	HbA1c baseline	Age baseline	BMI baseline	Weight baseline	eGFR baseline	Per cent HbA1c <7% drug	Per cent HbA1c <7% PBO	Weight loss PBO	Weight loss drug	Reduction HA1c PBO	Reduction HbA1c drug	Difference HbA1c
Dapagliflozin
Ferrannini et al15	7 to 10	7.84–8.01	50.6–52.7	32.3–33.6	88.8–94.2	NR	51	32	−2.2	−3.2	−0.23	−0.89	−0.66
Ji et al17	≥7.5 to ≤10.5	8.28–8.35	49.9–51.2	25.76–25.93	70.92–72.18	NR	50	21.3	−0.27	−2.25	−0.29	−1.11	−0.82
Kaku et al23	≥6.5 to ≤10	7.46–7.50	57.5–60.4	25.22–26.06	65.96–69.7	66.9–67.8	36	19	−0.84	−2.22	−0.06	−0.45	−0.39
Canagliflozin
Inagaki et al22	7 to 10	8.04	58.2–58.4	25.59 to 25.85	68.57–69.10	81.4–84.7	31.5	6.6	−0.76	−3.76	+0.29%	−0.74%	−1.03%
Stenlof et al13	≥7.0 to ≤10.0	8.0–8.1	55.1–55.7	31.3–31.8	85.8–87.6	NR	45, 62	21	NR	NR	0.14	−0.77; −1.03	−0.91; −1.17
Empagliflozin
Roden et al20	≥7.0 to ≤10.0	7.86–7.91	53.8–56.2	28.2–28.7	77.8–78.4	86.8–87.7	35, 44	12	−0.33	−2.26; −2.48	0.08	−0.66; −0.78	−0.74; −0.86
Luseogliflozin
Seino et al21	≥6.5 to ≤10.5	8.14–8.17	58.9–59.6	25.34–25.98	66.67–70.19	NR	NR	NR	−0.9	−2.7	+0.13	−0.63	−0.76
Tofogliflozin
Kaku et al23	≥7.3 to <10.3	8.34–8.45	56.6–58.6	24.99–26	67.26–71.20	83.78–86.78	NR	NR	−0.356	−2.23 −2.851 −2.971	−0.028	−0.767 −1.017 −0.870	−0.769 −0.990 −0.842

HbA1c in per cent; age in years; BMI in kg/m²; weight in kg; eGFR in mL/min/1.73 m².
BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; NR, not reported; PBO, placebo.